Items where authors include "Kollmeier, A"

Conference or Workshop Item

Mease, P, Helliwell, P orcid.org/0000-0002-4155-9105, Gladman, D et al. (10 more authors) (2022) Effect of Guselkumab a Selective IL-23p19 Inhibitor, on Axial-Related Endpoints in Patients With Active PsA: Results From a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years. In: Canadian Rheumatology Association Annual Meeting, 02-05 Feb 2022, Online.

Rahman, P, Ritchlin, C, Mease, P et al. (10 more authors) (2022) Long-term Safety of Guselkumab in Patients With Active Psoriatic Arthritis: Pooled Results From 3 Randomized Clinical Trials Through Up to 2 Years. In: Open Access Canadian Rheumatology Association Annual Meeting, 02-05 Feb 2022, Online.

Kavanaugh, A, Liu, Y, Deodhar, A et al. (8 more authors) (2021) Correlations Between Reductions in Fatigue Severity and Improvements in Physical Function and Clinical Response in Patients with Psoriatic Arthritis: Results from the Phase 3 DISCOVER Program. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Mease, P, Helliwell, PS orcid.org/0000-0002-4155-9105, Gladman, D et al. (10 more authors) (2021) Effect of Guselkumab (TREMFYA (R)), a Selective IL-23p19 Inhibitor, on Axial-Related Endpoints in Patients with Active PsA: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Coates, L, Ritchlin, C, Gossec, L et al. (12 more authors) (2021) Guselkumab Provides Sustained Domain-Specific and Comprehensive Efficacy as Assessed Using Composite Endpoints in Patients with Active Psoriatic Arthritis. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Orbai, A-M, Coates, L, Deodhar, A et al. (9 more authors) (2021) Guselkumab-Treated Patients with Psoriatic Arthritis Achieved Clinically Meaningful Improvements in General Health Outcomes Measured with PROMIS-29 Through 52 Weeks: Results from the Phase 3 DISCOVER-1 Trial. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Rahman, P, Ritchlin, C, Mease, P et al. (11 more authors) (2021) Long-term Safety of Guselkumab (TREMFYA (R)) in Patients with Active Psoriatic Arthritis: Pooled Results from 3 Randomized Clinical Trials Through up to 2 Years. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Mease, P, Foley, P, Reich, K et al. (14 more authors) (2021) Low Incidence of Gastrointestinal-related and Overall Serious Adverse Events Among Guselkumab-treated Patients: Pooled Analyses of VOYAGE 1 & 2 and DISCOVER 1 & 2 Through 1-Year. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Kavanaugh, A, Liu, Y, Deodhar, A et al. (8 more authors) (2021) Correlations Between Reductions in Fatigue Severity and Improvements in Physical Function and Clinical Response in Patients with Psoriatic Arthritis: Results from the Phase 3 Discover Program. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Behrens, F, Mease, PJ, Helliwell, P orcid.org/0000-0002-4155-9105 et al. (8 more authors) (2021) Efficacy of Guselkumab Across Basdai Components in Treating Axial-Related Symptoms of Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-Controlled Studies. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Coates, LC, Ritchlin, CT, Gossec, L et al. (12 more authors) (2021) Guselkumab Provides Sustained Domain-Specific and Comprehensive Efficacy as Assessed using Composite Endpoints in Patients with Active Psoriatic Arthritis. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Orbai, AM, Coates, LC, Deodhar, A et al. (9 more authors) (2021) Guselkumab-Treated Patients with Psoriatic Arthritis Achieved Clinically Meaningful Improvements in General Health Outcomes Measured with PROMIS-29 Through 52 Weeks: Results from the Phase 3 Discover-1 Trial. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Rahman, P, Helliwell, P orcid.org/0000-0002-4155-9105, Deodhar, A et al. (6 more authors) (2021) In Phase-3 Trials Discover 1 & 2, Guselkumab Reduced Fatigue over 52 Weeks in Patients with Psoriatic Arthritis and Demonstrated Independent Treatment Effects on Fatigue after Adjustment for Clinical Response (ACR20). In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Mease, PJ, Foley, P, Reich, K et al. (14 more authors) (2021) Low Incidence of Gastrointestinal-Related and Overall Serious Adverse Events among Guselkumab-Treated Patients: Pooled Analyses of Voyage 1 & 2 and Discover 1 & 2 Through 1-Year. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Ritchlin, CT, Rahman, P, Helliwell, P orcid.org/0000-0002-4155-9105 et al. (13 more authors) (2021) Pooled Safety Results from Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis through 1 Year. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Rahman, P, Ritchlin, C, Helliwell, P orcid.org/0000-0002-4155-9105 et al. (12 more authors) (2021) Integrated Safety Results of Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis through the Placebo-Controlled Periods. In: Twelfth International Congress on Spondyloarthritides, 09-11 Sep 2021, Virtual.

Ritchlin, C, Deodhar, A, Boehncke, W-H et al. (10 more authors) (2020) Guselkumab Efficacy and Safety in TNF-Inhibitor-Experienced and TNF-Inhibitor-Naive Patients with Active PsA: 1-Year Results of a Phase 3, Randomized, Controlled Study. In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.

Coates, L, Ritchlin, C, Gossec, L et al. (12 more authors) (2020) Guselkumab Provides Domain-Specific and Comprehensive Efficacy as Assessed Using Composite Endpoints in Patients with Active Psoriatic Arthritis. In: ACR Convergence 2020, 05-09 Nov 2021, Virtual.

Ritchlin, C, Helliwell, P orcid.org/0000-0002-4155-9105, Boehncke, W-H et al. (8 more authors) (2020) Guselkumab, an IL-23 Inhibitor That Specifically Binds to the IL23p19-Subunit, for Active Psoriatic Arthritis: One Year Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Patients Who Were Biologic-Naïve or TNFα Inhibitor-Experienced. In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.

Orbai, A-M, Coates, L, Deodhar, A et al. (8 more authors) (2020) Guselkumab-Treated Patients Achieved Clinically Meaningful Improvement in Systemic Symptoms as Measured with PROMIS Instrument: Results from Phase-3 Psoriatic Arthritis Trial DISCOVER 1. In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.

Orbai, AM, Coates, LC, Deodhar, A et al. (8 more authors) (2020) AB0813 GUSELKUMAB-TREATED PATIENTS ACHIEVED CLINICALLY MEANINGFUL IMPROVEMENT IN SYSTEMIC SYMPTOMS AS MEASURED WITH PROMIS INSTRUMENT: RESULTS FROM PHASE-3 PSORIATIC ARTHRITIS TRIAL DISCOVER 1. In: EULAR 2020, 03-06 Jun 2020, Online.

Rahman, P, Ritchlin, CT, Helliwell, P et al. (13 more authors) (2020) FRI0359 INTEGRATED SAFETY RESULTS OF TWO PHASE-3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS THROUGH THE PLACEBO-CONTROLLED PERIODS. In: EULAR 2020, 03-06 Jun 2020, Online.

Helliwell, P, Gladman, DD, Poddubnyy, D et al. (13 more authors) (2020) OP0054 EFFICACY OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF IL-23, ON ENDPOINTS RELATED TO AXIAL INVOLVEMENT IN PATIENTS WITH ACTIVE PSA WITH IMAGING-CONFIRMED SACROILIITIS: WEEK-24 RESULTS FROM TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES. In: EULAR 2020, 03-06 Jun 2020, Online.

Ritchlin, CT, Helliwell, P, Boehncke, WH et al. (8 more authors) (2020) SAT0397 GUSELKUMAB, AN IL-23 INHIBITOR THAT SPECIFICALLY BINDS TO THE IL23P19-SUBUNIT, FOR ACTIVE PSORIATIC ARTHRITIS: ONE YEAR RESULTS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PATIENTS WHO WERE BIOLOGIC-NAÏVE OR TNFΑ INHIBITOR-EXPERIENCED. In: EULAR 2020, 03-06 Jun 2020, Online.

Helliwell, P, Rahman, P, Deodhar, A et al. (6 more authors) (2020) SAT0421 GUSELKUMAB DEMONSTRATED AN INDEPENDENT TREATMENT EFFECT ON FATIGUE AFTER ADJUSTMENT FOR CLINICAL RESPONSE (ACR20) IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM PHASE-3 TRIALS DISCOVER 1 & 2. In: EULAR 2020, 03-06 Jun 2020, Online.

Deodhar, A, Helliwell, P, Boencke, W-H et al. (7 more authors) (2019) Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis Who Were Biologic-Naïve or Prior TNFα Inhibitor-Treated: Week 24 Results of a Phase 3, Randomized, Double-blind, Placebo-controlled Study. In: 2019 ACR/ARP Annual Meeting, 08-13 Nov 2019, Atlanta, GA, USA.